RXST INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit

Core Viewpoint - The RxSight class action lawsuit alleges that the company and its executives made misleading statements regarding the company's performance and financial guidance, leading to significant stock price declines [1][4][5]. Company Overview - RxSight is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery [3]. Allegations of the Lawsuit - The lawsuit claims that RxSight faced "adoption challenges" and structural issues that resulted in declining sales and utilization of its products [4]. - It is alleged that the company overstated the demand for its products, which contributed to its inability to meet previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second quarter financial results on July 8, 2025, which showed significant declines in sales and revenue, RxSight lowered its full year guidance by approximately $42.5 million at the midpoint [5]. Financial Impact - The lawsuit notes that RxSight's stock price fell nearly 38% following the announcement of disappointing financial results and guidance adjustments [5].